Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Financing Activities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cash from Financing Activities for 16 consecutive years, with $365000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 12.65% to $365000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $24.4 million, a 48.88% increase, with the full-year FY2023 number at $2.5 million, up 105.55% from a year prior.
  • Cash from Financing Activities was $365000.0 for Q3 2025 at Gyre Therapeutics, down from $22.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $49.5 million in Q1 2021 to a low of -$45.0 million in Q3 2022.
  • A 5-year average of $2.1 million and a median of $156000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 48612.5% in 2023, then skyrocketed 14227.56% in 2025.
  • Gyre Therapeutics' Cash from Financing Activities stood at $98000.0 in 2021, then plummeted by 46045.92% to -$45.0 million in 2022, then soared by 133.85% to $15.2 million in 2023, then crashed by 97.87% to $324000.0 in 2024, then increased by 12.65% to $365000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash from Financing Activities are $365000.0 (Q3 2025), $22.4 million (Q2 2025), and $1.3 million (Q1 2025).